by Suman Gupta
Revenue for Q2 FY22 of INR 3,520 Million, a growth of 42.0% (y-o-y) and 8.9% (q-o-q)
and for H1 FY22 of INR 6,751 Million, a growth of 53.0% (y-o-y)
EBITDA for Q2 FY22 of INR 650 Million, a growth of 91.1% (y-o-y) and 19.0% (q-o-q)
and EBITDA for H1 FY22 of INR 1,197 Million, a growth of 113.3% (y-o-y)
Bengaluru,November15,2021: HealthCareGlobal Enterprises Limited (“HCG”), the leader in India in speciality healthcare services focused on oncology and fertility today announced its financial results for the quarter (“Q2”) and six months ended September 30, 2021.
Highlights for quarter ended September 30th, 2021
-
Consolidated Income from Operations (“Revenue”) was INR 3,520 mn as compared to INR 2,479 mn in the corresponding quarter of the previous year, reflecting a year-on-year growth of 42.0%
-
Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was INR 650 mn, as compared to INR 340 mn in the corresponding quarter of the previous year, a growth of 91.1% year-on-year and 19.0% quarter-on-quarter
-
Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was INR 617 mn, as compared to INR 300 mn in the corresponding quarter of the previous year, a growth of 105.7% year-on-year and 20.5% quarter-on-quarter
-
Operating EBITDA for Existing centers was INR 598 mn, a growth of 81.7% year-on-year and 12.4% quarter- on-quarter, reflecting an Operating EBITDA margin of 21.9%
-
Operating EBITDA from New centers was INR 19 mn, as compared to loss of INR 29 mn in the corresponding quarter of the previous year and loss of INR 19 mn in the previous quarter
-
Consolidated Profit after Taxes and Minority Interest (“PAT”) was a profit of INR 1,031 mn, as compared to loss of INR 223 mn in the corresponding quarter of the previous year
INR million except earnings per share
Period ended Sep’21 |
Q2-FY22 |
Q2-FY21 |
Growth
|
|||||
Income from Operations |
3,520 |
2,479 |
42.0% |
|||||
EBITDA(1) |
650 |
340 |
91.1% |
|||||
EBITDA margin (%) |
18.5% |
13.7% |
||||||
Operating EBITDA (2) |
617 |
300 |
105.7% |
|||||
Op. EBITDA margin (%) |
17.5% |
12.1% |
||||||
PBT (3) |
1419 |
(323) |
NM |
|||||
PBT margin % |
40.3% |
-13.0% |
||||||
PAT (4) |
1031 |
(223) |
NM |
|||||
PAT margin % |
29.3% |
-9.0% |
||||||
Earnings per share (EPS) |
8.22 |
(1.94) |
NM |
|||||
(1) Profit before depreciation and amortization, finance costs, exceptional items and taxes
(2) EBITDA excluding other income
(3) Profit / (Loss) before tax and after share of profit / (loss) of equity accounted investee, exceptional items
(4) Profit / (Loss) for the period after share of profit / (loss) of equity accounted investee, taxes and minority interests, exceptional items
Business Updates for Q2 FY22
-
Record performance with ‘all-time high’ operating financials delivered across the business:
o Highest ever monthly and quarterly Revenue and EBITDA delivered during the quarter
o Strong sequential & yearly revenue growth on the back of higher footfalls
-
HCG New centers continued their scale-up trajectory:
o Strong revenue growth of 57.9% y-o-y and 10.1%q-o-q
o Recorded positive EBITDA with several centers witnessing turnaround in EBITDA (unit level)
-
Several regions delivered double-digit revenue growth on sequential basis on the back of gradual unlocking of the economy
o Maharashtra upsurge continued across all centers and delivered 17.5% revenue growth q-o-q
o East India witnessed a continuance in its growth path with 20.1% revenue growth q-o-q
o North India recorded a high growth of 42.1% q-o-q
-
Other highlights